<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Dermatology: Rheumatoid Arthritis Topic Collection</title>
    <link>http://archderm.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Mon, 22 Apr 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Mon, 29 Apr 2013 22:46:23 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archderm.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archderm.jamanetwork.com</webMaster>
    <item>
      <title>Neutrophilic Urticaria With Systemic Inflammation A Case Series  Neutrophilic Urticaria With Systemic Inflammation </title>
      <link>http://archderm.jamanetwork.com/article.aspx?articleID=1679360</link>
      <pubDate>Mon, 01 Apr 2013 00:00:00 GMT</pubDate>
      <author>Belani H, Gensler L, Bajpai U, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Importance&lt;/div&gt;Predominantly neutrophilic infiltrates are seen in a subset of patients with urticaria. The lesions tend to be less itchy and poorly responsive to standard therapy, including antihistamines. We describe 2 patients having neutrophilic urticaria with systemic inflammation (NUSI) without known connective tissue disorder or malignancy. We propose the term NUSI to help classify a previously undefined multisystemic inflammatory entity likely mediated by interleukin 1 (IL-1).&lt;div class="boxTitle"&gt;Observations&lt;/div&gt;Patient 1, a 47-year-old woman, was seen with urticaria and associated night sweats, fevers, and polyarticular arthritis. Acute-phase reactants were elevated with worsening of symptoms. Initial treatment with a combination of topical and systemic corticosteroids, antihistamines, and immunosuppressants was unsuccessful. A 100% clinical resolution was achieved with anakinra, an IL-1 receptor antagonist. Patient 2, a 24-year-old woman, was seen with urticaria and associated joint pain and swelling. Initial treatment included a combination of antihistamines, colchicine, and dapsone. Only colchicine provided moderate benefit but was stopped because of significant gastrointestinal tract discomfort. Anakinra was initiated; the patient achieved 100% control while receiving daily therapy.&lt;div class="boxTitle"&gt;Conclusions and Relevance&lt;/div&gt;The diagnosis of NUSI is important to consider in patients who are seen with antihistamine-resistant urticaria in combination with systemic inflammatory symptoms. Interleukin 1 blockade is a viable option for therapy.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">149</prism:volume>
      <prism:number xmlns:prism="prism">4</prism:number>
      <prism:startingPage xmlns:prism="prism">453</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">458</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jamadermatol.2013.2705</prism:doi>
      <guid>http://archderm.jamanetwork.com/article.aspx?articleID=1679360</guid>
    </item>
  </channel>
</rss>